Skip to main content
. Author manuscript; available in PMC: 2017 Sep 10.
Published in final edited form as: J Control Release. 2017 Jun 27;261:105–112. doi: 10.1016/j.jconrel.2017.06.022

Figure 5. Vismodegib increases intratumoral delivery of doxorubicin.

Figure 5

Quantification of doxorubicin (Dox) concentration in control and vismodegib-treated MiaPaCa2 pancreatic tumors as well as in kidney, liver and heart tissues. Doxorubicin (20 mg/kg) was injected intravenously to the animals 4 hours prior to sacrifice. Vismodegib increased the delivery of doxorubicin by 2-fold in vismodegib-treated compared to control-treated tumors (p < 0.05, n = 9). No significant differences were observed in drug delivery to normal tissues. Asterisk indicates statistically significant differences between compared groups (p < 0.05).